Roughly half of US adults have high blood pressure, and many remain above goal even on multiple medications. New approaches go beyond pills — a one-time procedure called renal denervation lowers blood pressure by quieting nerves in the kidney arteries, and a twice-yearly injection that silences a blood-pressure gene is in late-stage testing.
What's actually going on in research
Trials are testing once- or twice-yearly injections that target the angiotensinogen gene, renal denervation devices, new pill combinations, and treatments for resistant hypertension. Research also focuses on home blood-pressure monitoring strategies, hypertension in pregnancy, and reducing salt and stress at the population level.
Long-acting injections
A twice-yearly injection that silences a key blood-pressure gene is in late-stage trials and could replace daily pills for some people. Adherence is a major reason blood pressure stays high.
Renal denervation
A one-time catheter procedure quiets nerves in the kidney arteries and lowers blood pressure for years. It is now FDA-cleared, and trials are refining who benefits most.
Resistant hypertension
For people whose blood pressure stays high on three or more medications, new drugs that block aldosterone or endothelin are showing strong reductions in trials.
What to know before you search
Eligibility usually depends on average blood pressure readings, number of medications already tried, kidney function, and other heart-disease risk factors.
What types of trials are currently open
- New medication trials — Testing new blood-pressure drugs or longer-acting injections that may replace or reduce the need for daily pills.
- Device trials — Studies of renal denervation and other procedures that lower blood pressure without medication.
- Lifestyle and behavior trials — Testing diet, exercise, and stress-reduction programs designed to lower blood pressure.
- Prevention trials — Testing approaches in people with mildly elevated blood pressure to keep them from progressing.
- Observational studies — Following people with high blood pressure to learn what works in real-world settings.
Recently added Hypertension trials
Prevalence, Pathogenesis, and Prognosis of Pulmonary Hypertension in Dialysis Patients
This prospective multicenter longitudinal study aims to investigate the prevalence, pathogenesis, and prognosis of pulmonary hypertension in patients with end-stage renal disease undergoing chronic hemodialysis. The research seeks to identify specific clinical factors and biomarkers like angiopoietin-2 that contribute to the development of this condition, while evaluating the prognostic value of right ventricular function measured via TAPSE. Participants undergo a standardized screening echocardiogram the day after their intermediate dialysis session to determine the probability of pulmonary hypertension. Those identified as high-risk receive further diagnostic confirmation through right heart catheterization, respiratory function tests, and lung scans to clarify the underlying etiology. The protocol also evaluates the hemodynamic impact of high-flow arteriovenous fistulas and volume overload on pulmonary pressures. Clinical follow-up is conducted at baseline and subsequently at 6, 12, and 24 months to monitor patient outcomes and standardize therapeutic management according to established European guidelines.
Cardiometabolic Disease and Substrate Metabolism
This study's primary purpose is to determine the potential relationship between cardiometabolic disease, specifically insulin resistance (HOMA-IR), and maternal lipid oxidation.
Find Hypertension trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.